X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs J.B.CHEMICALS - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA J.B.CHEMICALS CIPLA/
J.B.CHEMICALS
 
P/E (TTM) x 33.7 17.8 190.0% View Chart
P/BV x 2.9 2.4 122.2% View Chart
Dividend Yield % 0.6 0.2 357.8%  

Financials

 CIPLA   J.B.CHEMICALS
EQUITY SHARE DATA
    CIPLA
Mar-18
J.B.CHEMICALS
Mar-16
CIPLA/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs663318 208.4%   
Low Rs479200 240.1%   
Sales per share (Unadj.) Rs189.0148.0 127.7%  
Earnings per share (Unadj.) Rs17.619.1 92.2%  
Cash flow per share (Unadj.) Rs34.023.9 142.1%  
Dividends per share (Unadj.) Rs3.000.50 600.0%  
Dividend yield (eoy) %0.50.2 271.9%  
Book value per share (Unadj.) Rs176.7128.9 137.1%  
Shares outstanding (eoy) m805.1284.82 949.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.7 172.7%   
Avg P/E ratio x32.513.6 239.3%  
P/CF ratio (eoy) x16.810.8 155.3%  
Price / Book Value ratio x3.22.0 161.0%  
Dividend payout %17.12.6 650.8%   
Avg Mkt Cap Rs m459,72421,951 2,094.3%   
No. of employees `00023.62.7 863.6%   
Total wages/salary Rs m26,9011,841 1,461.1%   
Avg. sales/employee Rs Th6,446.14,590.9 140.4%   
Avg. wages/employee Rs Th1,139.4673.4 169.2%   
Avg. net profit/employee Rs Th600.0592.1 101.3%   
INCOME DATA
Net Sales Rs m152,19312,551 1,212.6%  
Other income Rs m3,577542 660.4%   
Total revenues Rs m155,76913,093 1,189.7%   
Gross profit Rs m28,2642,055 1,375.6%  
Depreciation Rs m13,228412 3,207.6%   
Interest Rs m1,14296 1,193.6%   
Profit before tax Rs m17,4702,088 836.6%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-7750-   
Tax Rs m2,501469 533.2%   
Profit after tax Rs m14,1661,619 875.1%  
Gross profit margin %18.616.4 113.4%  
Effective tax rate %14.322.5 63.7%   
Net profit margin %9.312.9 72.2%  
BALANCE SHEET DATA
Current assets Rs m108,1417,778 1,390.4%   
Current liabilities Rs m38,3224,358 879.4%   
Net working cap to sales %45.927.2 168.4%  
Current ratio x2.81.8 158.1%  
Inventory Days Days9755 177.4%  
Debtors Days Days7480 93.0%  
Net fixed assets Rs m109,4115,713 1,915.2%   
Share capital Rs m1,610170 949.4%   
"Free" reserves Rs m140,68210,547 1,333.9%   
Net worth Rs m142,29210,937 1,301.0%   
Long term debt Rs m36,6210-   
Total assets Rs m228,60615,574 1,467.9%  
Interest coverage x16.322.8 71.4%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.70.8 82.6%   
Return on assets %6.711.0 60.8%  
Return on equity %10.014.8 67.3%  
Return on capital %10.020.0 49.9%  
Exports to sales %32.848.7 67.3%   
Imports to sales %07.1 0.0%   
Exports (fob) Rs m49,8836,115 815.8%   
Imports (cif) Rs mNA889 0.0%   
Fx inflow Rs m51,6916,169 837.9%   
Fx outflow Rs m21,0331,285 1,636.7%   
Net fx Rs m30,6584,884 627.7%   
CASH FLOW
From Operations Rs m14,6281,397 1,047.3%  
From Investments Rs m-8,540-320 2,666.3%  
From Financial Activity Rs m-3,855-1,196 322.4%  
Net Cashflow Rs m2,431-102 -2,376.4%  

Share Holding

Indian Promoters % 16.0 55.4 28.9%  
Foreign collaborators % 20.8 0.3 6,933.3%  
Indian inst/Mut Fund % 12.2 3.4 359.9%  
FIIs % 23.7 3.9 607.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 37.0 70.8%  
Shareholders   161,166 30,437 529.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   AUROBINDO PHARMA  MERCK LTD  ALEMBIC PHARMA  DR. REDDYS LAB  NOVARTIS  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Nov 14, 2018 (Close)

TRACK CIPLA

CIPLA - FDC LTD. COMPARISON

COMPARE CIPLA WITH

MARKET STATS